CAN
NBIX icon

Claraphi Advisory Network’s Neurocrine Biosciences NBIX Stock Holding History

Claraphi Advisory Network’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-75
Closed -$6K – 860
2020
Q1 		$6K Buy
+75
New +$7.34K ﹤0.01% 860

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Claraphi Advisory Network's NBIX Position: Q2 2020 in Review

Claraphi Advisory Network sold out of Neurocrine Biosciences (NBIX) in Q2 2020, closing a stake of 75 shares — an estimated $6K sold.

Claraphi Advisory Network first reported a position in NBIX in Q1 2020 and held it in 1 quarter. The position peaked at $6K in Q1 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q2 2020.

  • Claraphi Advisory Network reported no remaining Neurocrine Biosciences position as of Q2 2020 after selling out during the quarter.
  • Claraphi Advisory Network sold 75 Neurocrine Biosciences shares in Q2 2020, an estimated $6K.
  • Claraphi Advisory Network first reported a position in Neurocrine Biosciences in Q1 2020 and held it in 1 quarter.
  • Claraphi Advisory Network's Neurocrine Biosciences position peaked at $6K in Q1 2020.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2020.

Based on Claraphi Advisory Network's 13F filing for Q2 2020, filed 14 Aug 2020.